Project Grant R01HD113487
Award Date
8/7/24
Completion Date
4/30/29
Dollars Obligated
$756K
Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This federal Project Grant award totaling $815,573.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective is to study HIV-induced inflammation in perinatally infected adolescents on long-term antiretroviral therapy (ART) and define the viral factors driving this inflammation. The grant will support a unique cohort study of perinatally infected Kenyan adolescents on long-term ART,...
This Project Grant award totaling $1,673,778 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to characterize the HIV-1 proviral reservoir in neonates and infants receiving very early and enhanced antiretroviral therapy (ART) in combination with broadly neutralizing antibodies (bNAbs), with the goal of achieving ART-free remission. Key activities include quantifying and...
This $685,637 federal Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) is funding the "ENHANCING NOVEL RESEARCH FOR INFLAMMATION AND COGNITIVE HEALTH AMONG ADOLESCENTS AND YOUNG ADULTS LIVING WITH PERINATALLY ACQUIRED HIV AND ADVERSITY (ENRICH+)" research project. The award, made to The Trustees of Columbia University in the City of New York, will examine the relationship between immune dysfunction, inflammation, and...
This Project Grant award of $1,376,850.00 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to develop interventions for protecting HIV-exposed uninfected (HEU) infants against severe infections. The key objectives of the project are to: 1) define the immunogenomic and metabolomic profiles that explain the immune dysfunctions in HEU infants during the first year of life; 2) compare...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $2,705,914 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Maryland, Baltimore (UMB) to conduct research on the physiological impact of in-utero HIV exposure on hematopoietic stem cells (HSCs) and myeloid differentiation in HIV-exposed, uninfected (HEU) infants born to antiretroviral therapy-treated mothers. The research aims to unravel the cellular and molecular...
This federal Project Grant award for $498,000.00, awarded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support a longitudinal study to identify interactions between viruses, bacterial microbiota, and cellular responses to vaccination in HIV-exposed uninfected (IHEU) and HIV-unexposed (IHU) infants. The key objectives are to: 1) Integrate viral metagenome data with bacterial...
This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $2,207,322 to the University of Nebraska Medical Center (UNMC) for developing ultra-long-acting antiretroviral therapy (ART) formulations for HIV-1 treatment in pediatric populations. The key objective is to create a complete 6-month injectable ART regimen using integrase strand transfer inhibitors (INSTIs) like bictegravir and...
This federal Project Grant award, totaling $872,684.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of the project is to use single-cell multi-omic profiling techniques to investigate the role of transcriptionally active HIV-infected cells in driving chronic immune activation, despite effective antiretroviral therapy (ART). The research aims to identify and characterize the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $448,765 to Oregon Health & Science University (OHSU) to conduct research on the persistence of HIV-specific CD8+ T cell responses in early-treated Thai children. The primary objectives are to: (1) determine the magnitude, phenotype, and functionality of HIV-specific CD8+ T cells that persist in early-treated...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $645,900 to conduct comprehensive research on HIV drug resistance in Kenya as the country transitions to the "new antiretroviral therapy (ART) era." The primary awardee, The Miriam Hospital, will lead a multidisciplinary research team to prospectively investigate the extent and impact of transmitted and...